Greg Rossi
AstraZeneca (United Kingdom)(GB)
Publications by Year
Research Areas
Erythropoietin and Anemia Treatment, Iron Metabolism and Disorders, Hemoglobinopathies and Related Disorders, Pharmacological Effects and Toxicity Studies, Blood transfusion and management
Most-Cited Works
- → Prognostic factors in low grade (WHO grade II) gliomas of the cerebral hemispheres: the role of surgery.(1996)135 cited
- → A Randomized Comparison of Every-2-Week Darbepoetin Alfa and Weekly Epoetin Alfa for the Treatment of Chemotherapy-Induced Anemia in Patients With Breast, Lung, or Gynecologic Cancer(2004)104 cited
- → Randomized, Double-Blind, Active-Controlled Trial of Every-3-Week Darbepoetin Alfa for the Treatment of Chemotherapy-Induced Anemia(2006)104 cited
- → Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: A randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa(2005)90 cited
- → Randomized Comparison of Every-2-Week Darbepoetin Alfa and Weekly Epoetin Alfa for the Treatment of Chemotherapy-Induced Anemia: The 20030125 Study Group Trial(2006)78 cited
- → A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia(2003)55 cited
- → Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy‐induced anemia(2007)40 cited
- → Efficacy and Safety of Every-2-Week Darbepoetin Alfa in Patients with Anemia of Cancer: A Controlled, Randomized, Open-Label Phase II Trial(2007)30 cited
- → Treatment of Chemotherapy-Induced Anemia in Breast Cancer: Results of a Randomized Controlled Trial of Darbepoetin Alfa 200 μg Every 2 Weeks Versus Epoetin Alfa 40,000 U Weekly(2005)26 cited
- A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome.(2006)